Video
Author(s):
Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, explains which patients with metastatic castration-resistant prostate cancer (mCRPC) are optimal for treatment with PARP inhibitors. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with mCRPC.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.